Mariner’s Esperion Therapeutics ESPR Stock Holding History

Mariner’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$865K	Buy	273,734 +99,941	+58%	+$280K	﹤0.01%	2064
2026 Q1	$476K	Sell	173,793 -104,868	-38%	-$332K	﹤0.01%	2526
2025 Q4	$1.03M	Sell	278,661 -23,853	-8%	-$77.1K	﹤0.01%	1934
2025 Q3	$802K	Buy	+302,514	New	+$585K	﹤0.01%	2076
2023 Q4	–	Sell	-26,130	Closed	-$25.6K	–	3087
2023 Q3	$25.6K	Buy	26,130 +4,141	+19%	+$5.99K	﹤0.01%	2830
2023 Q2	$30.6K	Buy	+21,989	New	+$30.7K	﹤0.01%	2754
2023 Q1	–	Sell	-17,786	Closed	-$111K	–	2817
2022 Q4	$111K	Buy	17,786 +4,738	+36%	+$33.9K	﹤0.01%	2498
2022 Q3	$87K	Buy	+13,048	New	+$89.6K	﹤0.01%	2232

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Mariner's ESPR Position: Q2 2026 in Review

Mariner increased its Esperion Therapeutics (ESPR) stake by 58% in Q2 2026, buying an estimated $280K and bringing the position to 273,734 shares worth $865K. The position accounts for ﹤0.01% of the portfolio, ranked #2064.

Mariner first reported a position in ESPR in Q3 2022 and has held it in 8 quarters since. The position peaked at $1.03M in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Mariner held 273,734 shares of Esperion Therapeutics worth $865K as of Q2 2026.
Mariner bought 99,941 Esperion Therapeutics shares in Q2 2026, an estimated $280K.
Esperion Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2064 holding.
Mariner first reported a position in Esperion Therapeutics in Q3 2022 and has held it in 8 quarters since.
Mariner's Esperion Therapeutics position peaked at $1.03M in Q4 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.